Evaluation of PET-CT Scanner Performances to Detect Infra-centimetric Lesions in Patients With Cancer
NCT ID: NCT03956459
Last Updated: 2021-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2019-07-25
2021-02-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
For each patient, two consecutive PET-CT scanner will be performed using the "Discovery MI" and "Discovery IQ" PET-CT scanner systems.
Virtual lesions will then be created on images obtained. Images will be interpreted by two independent observers.
The study participation of each patient will be a maximum of 24 hours.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prognostic PET/CT Model in Non Small Cell Lung Cancer
NCT03199599
PET-CT in the Initial Staging of Breast Cancer and in the Early Assessment of Response to Neoadjuvant Chemotherapy
NCT02599974
Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers
NCT01421953
Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET
NCT00904410
Evaluation of a New Generation of PET-CT OMNI
NCT05154877
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with a cancer
Patients with a cancer for which a FDG-PET scanner must be performed
For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:
* "Discovery MI"
* "Discovery IQ"
Only one contrast agent injection (FDG) will be given for both scanners.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Patients with a cancer for which a FDG-PET scanner must be performed
For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:
* "Discovery MI"
* "Discovery IQ"
Only one contrast agent injection (FDG) will be given for both scanners.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. A patient with a cancer for which a FDG-PET (fluorodeoxyglucose-positron emission tomography) must be performed according to the standard practices
3. OMS ≤ 1, Karnofsky Index \> 70.
4. Negative pregnancy test at inclusion.
5. Patient able to maintain a lying position in a strict supine position twice.
6. Patient affiliated to a Social Health Insurance in France.
7. Patient who has signed informed consent prior inclusion in the study and before any specific procedures for the study.
Exclusion Criteria
2. Patient with a formal contraindication usual for certain imaging procedures (severe claustrophobia, wearing a heart valve, pacemaker, etc.)
3. Pregnant or breastfeeding woman
4. Any psychological, family, geographical or sociological condition that does not allow medical follow-up and/or procedures provided for in the study protocol to be respected
5. Patient protected by law
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Claudius Regaud
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19 GENE 03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.